Last quarter (Q2 2023), Omega Therapeutics's total revenue was $759.00K, an increase of 59.45% from the same quarter last year. In Q2, Omega Therapeutics's net income was $-29.69M. See Omega Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 2.60M	$ 2.07M	$ 144.00K	$ 0.00	$ 0.00
Cost of Revenue	$ 1.73M	$ 3.02M	$ 1.71M	-	-
Gross Profit	$ 277.00K	$ -949.00K	$ -1.56M	-	-
Operating Expense	$ 114.48M	$ -104.84M	$ -66.18M	$ 28.64M	$ 17.34M
Operating Income	$ -113.61M	$ -102.77M	$ -66.03M	$ -28.64M	$ -17.34M
Net Non Operating Interest Income Expense	$ 2.76M	$ 1.30M	$ 998.00K	$ -777.00K	$ -595.00K
Other Income Expense	$ 55.00K	$ 157.00K	$ 1.34M	$ -25.00K	$ -11.00K
Pretax Income	$ -111.59M	$ -102.70M	$ -68.28M	$ -29.45M	$ -17.95M
Tax Provision	$ -147.80M	$ -147.80M	$ -125.80M	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-
Net Income Common Stockholders	$ -111.59M	$ -102.70M	$ -68.28M	$ -29.45M	$ -17.95M
Basic EPS	$ -2.64	$ -2.14	$ -3.05	$ -1.14	$ -0.69
Diluted EPS	$ -2.22	$ -2.14	$ -3.05	$ -1.14	$ -0.69
Basic Average Shares	$ 201.43M	$ 47.88M	$ 22.40M	$ 25.91M	$ 25.91M
Diluted Average Shares	$ 201.43M	$ 47.88M	$ 22.40M	$ 25.91M	$ 25.91M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	$ 116.22M	$ -101.82M	$ -64.47M	$ 28.64M	$ 17.34M
Net Income From Continuing And Discontinued Operation	$ -111.59M	$ -102.70M	$ -68.28M	$ -29.45M	$ -17.95M
Normalized Income	$ -25.80M	-	-	$ -29.45M	$ -17.95M
Interest Expense	-	-	-	$ 777.00K	$ 595.00K
EBIT	$ -114.63M	$ -104.22M	$ -68.37M	$ -28.67M	$ -17.35M
EBITDA	$ -78.45M	$ -97.88M	$ -66.85M	$ -27.52M	$ -16.56M

Currency in USD

Omega Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing